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national pharmacy (Apoteket AB). Costs were calculated from
a societal perspective by multiplying quantities of resources
used with unit costs (presented in Euros 2007). RESULTS: In
Sweden, about 326,100 patients over 54 years suffer from
acute insomnia (DSM-IV 307.42), a prevalence of about 12%
in this age group. The associated costs exceed €151 million per
year. About 44% are direct costs (outpatient care €40.4 m,
drugs €22.5 m, diagnostic examinations €0.48 m, specialist
visits €0.47 m and inpatient care €0.22 m) and 56% indirect
costs (presenteeism €78.5 m, absenteeism €6.6 m and occupa-
tional and domestic accidents related to daytime dysfunction
caused by poor sleep and current treatment €0.91 m and
€0.57 m, respectively). Other relevant cost items that were not
incorporated in this estimate, due to the high degree of uncer-
tainty, include: cognitive behavioural treatment, productivity
losses due to early retirement, medical costs due to co-
morbidities aggravated by insomnia, side-effects of current
treatment (incl. increased risk of trafﬁc accidents, tolerance,
dependence and withdrawal symptoms), and quality of life
losses. CONCLUSIONS: Our results conﬁrm that insomnia
presents a substantial clinical and economic burden. The
annual cost per patient (€463) is consistent with estimates for
e.g. Germany, France and the US. As a large share of the costs
fall outside the health care system, a societal perspective is
important when evaluating treatments of insomnia.
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OBJECTIVES: To generate national estimates of the inpatient
economic burden of key medical conditions among Asian-
American and Paciﬁc Islander (AAPI) females hospitalized in the
United States in 2005. Conditions analyzed were based upon
research conducted by the US Department of Health and Human
Services, Ofﬁce of Women’s Health, which identiﬁed conditions
of particular concern for this underserved population.
METHODS: Data from the 2005 HCUP Nationwide Inpatient
Sample (NIS) database were analyzed for 438,577 hospital stays
(unweighted = 91,092) for AAPI females. Among these, we iden-
tiﬁed stays in which the primary or second diagnosis, using
relevant ICD-9-CM diagnosis codes, was for tuberculosis (TB),
Hepatitis B (HBV), osteoporosis, cervical cancer (CC), and breast
cancer (BC). Using sampling weights provided with the NIS
dataset, national estimates of mean per-discharge length of stay
(LOS) and total costs, and aggregate (i.e., summed across all
discharges) total days and costs were estimated for each condi-
tion. RESULTS: Among hospitalizations for AAPI women in
2005, we found 485 hospitalizations for TB (with relevant
primary or second diagnosis only), 1237 for HBV, 672 for
osteoporosis, 490 for CC, and 1594 for BC. For each condition,
the mean per-discharge LOS and aggregate total days were 12.3
and 5611; 4.7 and 5804; 3.5 and 2325; 4.7 and 2316; and 2.7
and 4379 days, respectively. Finally, for each condition, the mean
per-discharge and aggregate total costs were $20,563 and
$9,099,718, $10,230 and $11,408,636, $8,284 and $5,269,951,
$10,174 and $4,472,145, and $8,040 and $11,655,081, respec-
tively. CONCLUSIONS: In this study we examined the inpatient
economic burden of illnesses that are of concern for AAPI
women in the US. The total cost incurred for just these 5 condi-
tions (4,478 discharges) was in excess of $40,000,000. Policy
and other decision makers should be aware of the burden of these
conditions as strategies to address these illnesses among this
minority population are developed.
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OBJECTIVES: To assess health care costs associated with a
diagnosis of preeclampsia or hypertension during pregnancy by
describing 5-month antepartum and delivery, and 3-month post-
partum health care costs. METHODS: Pregnancy episodes
(1999–2005) for female claimants ages 15–55 who met continu-
ous enrollment criteria were constructed using a U.S. employer-
based insurance claims database. Episodes were stratiﬁed based
on a diagnosis of preeclampsia (ICD-9 642.4–642.7; N = 2,435),
hypertension during pregnancy (ICD-9 642.0, 642.1, 642.3,
642.9; N = 2,419), or absence of either of these diagnoses
(N = 39,597). Pregnancy-related maternal (5-month antepartum
and delivery, and 3-month postpartum) and neonatal (3-month
postpartum) health care costs were compared using nonparamet-
ric Wilcoxon rank-sum tests, with mean values reported here.
RESULTS: Antepartum and delivery costs were highest for the
preeclampsia group ($13,491), followed by the hypertension
($8,899) and comparison ($8,075) groups (between-group dif-
ferences p < 0.001). Inpatient costs in the preeclampsia group
were 58% ($11,031 vs. $6,961; p < 0.001) and 63% ($11,031
vs. $6,781; p < 0.001) greater than in the hypertension and com-
parison groups, respectively. Maternal postpartum medical costs
in the preeclampsia, hypertension, and comparison groups were
$1623, $1028, and $741, respectively (between-group differ-
ences p < 0.001). Neonatal costs in the preeclampsia group were
much higher than those in the hypertension and comparison
groups ($7035 vs. $2784; p < 0.001 and $7035 vs. $2484;
p < 0.001). More than 60% of all neonatal costs in the preec-
lampsia group were associated with neonatal or pediatric inten-
sive care unit (NICU/PICU) services, compared to less than 40%
in both the hypertension and comparison groups. Total maternal
and neonatal postpartum costs were $8658, $3812, and $3226,
respectively (between-group differences p < 0.001). CONCLU-
SIONS: Pregnancies with a preeclampsia diagnosis are associated
with signiﬁcantly higher maternal antepartum and delivery costs,
and all postpartum costs. Neonatal costs are also signiﬁcantly
higher, largely due to NICU/PICU care of babies born to mothers
with a diagnosis of preeclamspia.
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OBJECTIVES: To evaluate, in a real-life clinical setting, the
utilisation, cost and outcomes of assisted reproduction treatment
(ART) with rFSH and assess whether the economic burden is
consistent with that established by the UK National Institute for
Health and Clinical Excellence (NICE). METHODS: Study
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patients were women receiving ‘fresh’ cycles of IVF/ICSI from
October 2001 to January 2006 at a UK ART unit that treats
National Health Service and privately funded patients. All
patients were treated with rFSH (Puregon™) for ovarian stimu-
lation. Rates of ongoing pregnancies per cycle and live birth rates
were calculated from clinic records. Drug use was determined
using pharmacy dispensing data. Costing for clinic procedures
was based on a ﬁnancial audit of the centre. Costs were applied
at UK 2007 prices. RESULTS: After excluding non IVF/ICSI
cycles, those lacking pharmacy data and complete cycle data we
analysed 1418 cycles undertaken by 1001 women. Mean dura-
tion of ovarian stimulation was 9.1 days (95%CI: 9.0–9.3 days).
The clinical pregnancy rate/cycle was 36.4% (95%CI: 33.9–
39%), the ongoing pregnancy rate was 24.4% (95%CI: 22.2%–
26.7%), and the live birth rate was 22% (95%CI: 19.7–24.2%).
The average rFSH dose/cycle prescribed was 1855 units (SD:
561), whereas the average dispensed dose/cycle was 1891 units
(SD: 540). The average cost of rFSH/cycle was £646 (SD: 219).
Average cost/cycle for concomitant medications and procedures
was £159 (SD: 122) and £2,127 (SD: 349), respectively. The
average total cost/cycle was £2.932 (SD: 422). The average cost/
clinical pregnancy, cost/ongoing pregnancy and cost/live birth
were £8,058, £12,017 and £13,326, respectively. CONCLU-
SIONS: While IVF/ICSI outcomes in this real-life clinical setting
were similar to UK averages, the cost of rFSH/cycle was lower
than that estimated in the NICE guidelines. These ﬁndings
suggest that NICE should revisit the affordability of funding
recommended levels of IVF/ICSI, taking efﬁcient drug delivery
practices into account.
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OBJECTIVES: To assess the long-term effects of growth
hormone (GH) treatment on physical features, safety and health-
related quality of life (HRQoL) in patients with the Prader-Willi
syndrome (PWS), as compared to general population. PWS is a
complex genetic disorder characterized by e.g. mental retarda-
tion, behavioral disorders, obesity, hypogonadism, and short
stature. METHODS: All 22 known Finnish paediatric patients
aged 2–10 years with PWS were contacted for participation in a
clinical study of one year between 1996 and 1998 for treatment
with GH (somatropin, 0.1 IU/kg/d); 20 patients participated.
Thereafter, they were treated in their own hospital districts with
various GH regimens. The subjects were invited to a follow-up
study consisting of one visit in 2007. Altogether 19 out of the 20
in the original study participated in the follow-up and underwent
a comprehensive evaluation, including HRQoL measurement by
the 16D. The 16D is a generic, comprehensive, 16-dimensional
(mobility, seeing, hearing, breathing, sleeping, eating, speech,
elimination, going to school, mental function, discomfort and
symptoms, depression, distress, vitality, appearance, and getting
and having friends), self-administered measure of HRQoL for
adolescents, and it can be used both as a proﬁle and single score
measure. Pre-existing data from 1995 of a sample of Finnish
age-matched population (n = 239) were used for comparison
using the independent samples t-test. Results for the physical
outcomes are reported separately. RESULTS: The mean 16D
score was 0.851 for the study patients and 0.949 for the com-
parator population; the difference is statistically signiﬁcant
(p = 0.001). The patients were worse off than the general popu-
lation on the dimensions of mobility, breathing, speech, mental
function, going to school, discomfort and symptoms, and getting
and having friends. CONCLUSIONS: Despite GH treatment, the
self-perceived HRQoL of these adolescent and young, adult PWS
patients remains poor on several dimensions and overall com-
pared with age-matched general population.
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OBJECTIVES: To assess the psychometric performance of the
Children’s Dermatology Quality of Life Index (CDQoL) in
Turkish pediatric dermatology patients. The CDQoL is a speciﬁc
quality of life index and which measures the impact of derma-
tology symptoms on QoL. METHODS: The health-related
quality of life (HRQoL) is measured in a sample of 90 patients
with dermatological problem using both the Turkish version of
the CDQoL and the Short Form 10 (SF-10) instruments.
RESULTS: The internal consistency within the domains of the
CDQoL was good, with Cronbach’s Alpha values 0.78 for the
CDQoL and 0.91 for the SF-10. Signiﬁcant correlations were
observed between the total scores of the CDQoL and the SF-10.
CONCLUSIONS: Overall, the results indicated that the psycho-
metric performance of the CDQoL in the study sample was quite
good and the instrument was found to be valid and reliable. The
instrument is likely to be suitable for use in clinical studies of
chronic dermatological diseases in Turkey.
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OBJECTIVES: The short, self administered Menopause Speciﬁc
Quality of Life Questionnaire (MSQoL) is a speciﬁc quality of
life instrument which measures the impact of menopause symp-
toms on QoL. This study aims to adapt the MSQoL question-
naire into Turkish (for Turkish) culture and check the
questionnaire psychometric properties. METHODS: The origi-
nal instrument was translated and back translated by two inde-
pendent translators. For psychometric measures, a small sample
was used to check the initial comprehension and factibility. Cron-
bach’s Alfa was used to assess reliability and factor analysis to
assess dimensionality. The EuroQol questionnaire and corre-
sponding Visual Analogue Scales were used for concurrent valid-
ity. RESULTS: 160 women with menapause syndrom were
participated. Mean age was 49. The reliability was good
(Alpha = 0.97) and all dimensions eigenvalues higher than 1.0,
explaning 78.9% of avaliable variability. All items loaded on
own dimensions. Correlations were moderate with EuroQol and
VAS. CONCLUSIONS: The Menapause Speciﬁc Quality of Life
Questionnaire has good psychometric properties. It is also cap-
able to discriminate women with a menapause.
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